Po‐Lan Su

714 total citations · 1 hit paper
56 papers, 407 citations indexed

About

Po‐Lan Su is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Po‐Lan Su has authored 56 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in Po‐Lan Su's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Po‐Lan Su is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Po‐Lan Su collaborates with scholars based in Taiwan, United States and China. Po‐Lan Su's co-authors include Chien‐Chung Lin, Wu‐Chou Su, Szu‐Chun Yang, Yau‐Lin Tseng, Yi‐Lin Wu, Sheng‐Hsiang Lin, Chung‐Liang Ho, Wu‐Wei Lai, Naoki Furuya and Zihai Li and has published in prestigious journals such as SHILAP Revista de lepidopterología, ACS Nano and PLoS ONE.

In The Last Decade

Po‐Lan Su

51 papers receiving 402 citations

Hit Papers

Recent advances in therapeutic strategies for non-small c... 2025 2026 2025 5 10 15
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recent advances in therapeutic strategies for non-small cell lung cancer
    2025 15 citations Po‐Lan Su, Naoki Furuya et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Po‐Lan Su Taiwan 12 256 197 68 48 47 56 407
Masahiro Katsurada Japan 11 197 0.8× 175 0.9× 77 1.1× 24 0.5× 42 0.9× 29 391
Takashi Haku Japan 10 133 0.5× 195 1.0× 84 1.2× 43 0.9× 31 0.7× 29 438
Masataka Hirabayashi Japan 12 355 1.4× 214 1.1× 44 0.6× 51 1.1× 59 1.3× 27 480
Yuan Cheng China 10 96 0.4× 71 0.4× 90 1.3× 50 1.0× 42 0.9× 49 341
Luis Cabezón‐Gutiérrez Spain 10 107 0.4× 148 0.8× 74 1.1× 21 0.4× 56 1.2× 44 337
Franciele Hinterholz Knebel Brazil 11 156 0.6× 114 0.6× 142 2.1× 39 0.8× 61 1.3× 21 368
Parham Khosravi‐Shahi Spain 10 83 0.3× 124 0.6× 68 1.0× 24 0.5× 66 1.4× 22 319
Siyuan Huang China 11 117 0.5× 88 0.4× 220 3.2× 29 0.6× 127 2.7× 26 414
Ziqing Zhou China 11 198 0.8× 36 0.2× 59 0.9× 26 0.5× 22 0.5× 48 375

Countries citing papers authored by Po‐Lan Su

Since Specialization
Citations

This map shows the geographic impact of Po‐Lan Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po‐Lan Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po‐Lan Su more than expected).

Fields of papers citing papers by Po‐Lan Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po‐Lan Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po‐Lan Su. The network helps show where Po‐Lan Su may publish in the future.

Co-authorship network of co-authors of Po‐Lan Su

This figure shows the co-authorship network connecting the top 25 collaborators of Po‐Lan Su. A scholar is included among the top collaborators of Po‐Lan Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po‐Lan Su. Po‐Lan Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Johns, Natalie, Songzhu Zhao, Po‐Lan Su, et al.. (2025). CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches. Journal of the National Comprehensive Cancer Network. 23(3.5). 1 indexed citations
3.
Su, Po‐Lan, Naoki Furuya, Atif Asrar, et al.. (2025). Recent advances in therapeutic strategies for non-small cell lung cancer. Journal of Hematology & Oncology. 18(1). 35–35. 15 indexed citations breakdown →
4.
5.
Su, Po‐Lan, Naoki Furuya, Meixiao Long, et al.. (2024). DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Molecular Cancer. 23(1). 97–97. 25 indexed citations
6.
7.
Kuo, Chin‐Wei, et al.. (2023). Navigating the challenges of invasive pulmonary aspergillosis in lung cancer treatment: a propensity score study. Therapeutic Advances in Medical Oncology. 15. 2643190–2643190. 5 indexed citations
8.
Chang, Chao‐Chun, et al.. (2023). Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy. Frontiers in Oncology. 13. 1238876–1238876. 2 indexed citations
9.
Kuo, Chih‐Hsi S., Po‐Lan Su, Yu‐Feng Wei, et al.. (2023). T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study). PubMed Central. 3 indexed citations
10.
11.
Wu, Chi‐Jung, Cong-Tat Cia, Hsuan‐Chen Wang, et al.. (2022). Clinical and Microbiological Characteristics of Culture-Positive, Influenza-Associated Pulmonary Aspergillosis: A Single-Center Study in Southern Taiwan, 2016–2019. Journal of Fungi. 8(1). 49–49. 9 indexed citations
12.
Yang, Szu‐Chun, Chao‐Chun Chang, Chia‐Ying Lin, et al.. (2021). Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors. Thoracic Cancer. 13(2). 182–189. 3 indexed citations
13.
Tsai, Chin-Shiang, et al.. (2021). Respiratory etiological surveillance among quarantined patients with suspected lower respiratory tract infection at a medical center in southern Taiwan during COVID-19 pandemic. Journal of Microbiology Immunology and Infection. 55(3). 428–435. 7 indexed citations
14.
Su, Po‐Lan, Szu‐Chun Yang, Yi‐Lin Wu, et al.. (2021). Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. Lung Cancer. 158. 137–145. 7 indexed citations
15.
Su, Po‐Lan, et al.. (2021). Electrical Impedance Tomography Analysis Between Two Similar Respiratory System Compliance During Decremetal PEEP Titration in ARDS Patients. Journal of Medical and Biological Engineering. 41(6). 888–894. 2 indexed citations
16.
Kuo, Chin‐Wei, Po‐Lan Su, Cong-Tat Cia, et al.. (2021). Invasive pulmonary aspergillosis is associated with cytomegalovirus viremia in critically ill patients - A retrospective cohort study. Journal of Microbiology Immunology and Infection. 55(2). 291–299. 13 indexed citations
17.
Su, Po‐Lan, et al.. (2019). Alpha-1 Adrenergic-Antagonist Use Increases the Risk of Sleep Apnea: A Nationwide Population-Based Cohort Study. Journal of Clinical Sleep Medicine. 15(11). 1571–1579. 5 indexed citations
18.
Wu, Yi‐Lin, et al.. (2018). The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS ONE. 13(2). e0192161–e0192161. 30 indexed citations
19.
Hsiue, Tzuen‐Ren, et al.. (2018). Comparison of different staging methods for COPD in predicting outcomes. European Respiratory Journal. 51(3). 1700577–1700577. 21 indexed citations
20.
Su, Po‐Lan, et al.. (2014). Simulation of Late Inspiratory Rise in Airway Pressure During Pressure Support Ventilation. Respiratory Care. 60(2). 201–209. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahiro Katsurada Breakdown of academic impact, for papers by Takashi Haku Breakdown of academic impact, for papers by Masataka Hirabayashi Breakdown of academic impact, for papers by Yuan Cheng Breakdown of academic impact, for papers by Luis Cabezón‐Gutiérrez Breakdown of academic impact, for papers by Franciele Hinterholz Knebel Breakdown of academic impact, for papers by Parham Khosravi‐Shahi Breakdown of academic impact, for papers by Siyuan Huang Breakdown of academic impact, for papers by Ziqing Zhou
Rankless by CCL
2026